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Abstract
Dengue viral (DENV) pathogenesis and vaccine studies are hampered by the lack of an ideal animal model mimicking human disease and
eliciting an adaptive human immune response. Although currently available animal models have been very useful in dissecting some key aspects of
disease pathogenesis, a major limitation with these is the lack of a human immune response. In this study, we sought to overcome this difficulty by
utilizing a novel mouse model that permits multi-lineage human hematopoiesis and immune response following transplantation with human
hematopoietic stem cells. To generate immunocompetent humanized mice, neonatal RAG2−/−γc
−/− mice were xenografted with human CD34+
hematopoietic stem cells, resulting in de novo development of major functional cells of the human adaptive immune system. To evaluate
susceptibility to dengue viral infection, humanized mice were challenged with DEN-2 serotype. Viremia lasting up to 3 weeks was detected in
infected mice with viral titers reaching up to 106.3 RNA copies/ml. Fever characteristic of dengue was also noted in infected mice. Presence of human
anti-dengue antibodies was evaluated using an antibody capture ELISA. Anti-dengue IgM was first detected by 2 weeks post-infection followed by
IgG at 6 weeks. Sera from some of the infected mice were also found to be capable of dengue virus neutralization. Infected mouse sera showed
reactivity with the viral envelope and capsid proteins in immunoprecipitation assay. These results demonstrate for the first time that humanized mice
are capable of dengue viral primary human immune responses thus paving the way for new dengue immunopathogenesis and vaccine studies.
© 2007 Elsevier Inc. All rights reserved.Keywords: Dengue pathogenesis; Humanized mice; Dengue animal model; Dengue immunity; Rag-hu mice; Humice; Dengue viral infection; Dengue antibody
dependent enhancement; Dengue neutralization; Dengue hemorrhagic feverIntroduction
Dengue virus (DENV) is a medically important mosquito-
borne flavivirus. Four antigenically distinct serotypes, DEN-1
through DEN-4, exist. All dengue serotypes infect humans
causing a range of illness from subclinical infection to acute
dengue fever to the severe and sometimes fatal vascular leakage
conditions of dengue hemorrhagic fever/dengue shock syn-
drome (DHF/DSS). There are over 2.5 billion people living in
areas at risk for infection and it is estimated that between 50–100
million cases of dengue fever and 500,000 cases of DHF/DSS⁎ Corresponding author. Fax: +1 970 491 0603.
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doi:10.1016/j.virol.2007.06.005occur each year, making dengue a worldwide health threat and
the most important arboviral disease of humans (Mackenzie et
al., 2004). Currently there are no licensed vaccines or anti-viral
treatments available although many are under development.
Molecular aspects of the virus have been studied extensively
leading to a good understanding of viral structure, replication
and genetic variability (Clyde et al., 2006). However, the
pathogenesis of dengue appears to be complex. Numerous viral,
immune and other host factors have been implicated in
determining the severity of disease (Clyde et al., 2006; Gubler,
1998; Kurane and Ennis, 1997). Primary infection confers
lifelong immunity to the infecting serotype but not to the other
three DENV serotypes, while secondary infection with a
different serotype is associated with an increased risk of DHF/
DSS (Halstead, 1988; Halstead and O'Rourke, 1977a, 1977b;
Kliks et al., 1989). Antibody dependent enhancement (ADE) of
infection, in which subneutralizing levels of antibody mediate
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has been proposed as a mechanism to explain this increased
disease severity in secondary infections (Halstead, 1988;
Halstead and O'Rourke, 1977a, 1977b; Kliks et al., 1989).
Although cells of the monocyte/macrophage and dendritic
lineages are believed to be primary viral targets (Tassaneetrithep
et al., 2003; Wu et al., 2000), many other cell types of lymphoid
(Lin et al., 2002; Mentor and Kurane, 1997; Theofilopoulos et
al., 1976), endothelial (Andrews et al., 1978; Avirutnan et al.,
1998; Huang et al., 2000b) and hepatic (Marianneau et al.,
1996) origin have also been postulated to support viral infection
and replication. The extent to which different cell types and
target organs are involved in dengue pathogenesis remains
unclear.
A major limitation to the understanding of dengue virus
pathogenesis and immunity has been the lack of an ideal animal
model. Primates can be infected by DENV but do not exhibit
symptoms of disease (Scherer et al., 1978). Several mouse
models for dengue infection have been developed. Intracerebral
inoculation of suckling mice results in DENV infection and thus
has been useful for virus propagation (Schlesinger, 1977). A/J
mice (Huang et al., 2000a) and BALB/c mice (Paes et al., 2005)
support limited levels of virus replication when inoculated with
high titers of DENV. Interferon-deficient mice with intact
adaptive immunity have been useful in the study of some
aspects of pathogenesis and protective immunity since they
support virus replication followed by death (Johnson and
Roehrig, 1999; Shresta et al., 2006).
Compared to these conventional animal models, in vivo
systems that incorporate human cells susceptible to dengue viral
infection have the advantage of achieving replication of the virus
in a physiological setting. In this regard, use of immunodeficient
SCID mice engrafted with human cells or cell lines has
broadened the scope of dengue pathogenesis studies. Infection
of SCID mice engrafted with human hepatocarcinoma (HepG2)
(An et al., 1999) or erythroleukemia cells (K562) (Lin et al.,
1998) led to sustained dengue viral infection and recapitulated
some aspects of dengue pathogenesis. Similarly, immunodefi-
cient NOD-SCID mice engrafted with human cord blood
hematopoietic progenitor cells were found to be susceptible to
DENV infection and showed signs typical of dengue, namely,
fever and thrombocytopenia (Bente et al., 2005). However, a
major deficiency of these human cell engrafted models is lack of
an immune response. Therefore, despite being useful for limited
pathogenesis studies and potential therapeutic drug testing, they
are inadequate for human immunity and antibody dependant
enhancement of infection studies. However, recent advances in
the creation of improved humanized mouse models which are
capable of recapitulating human immune responses have paved
the way for new avenues of investigation.
Prominent among these new models is the humanized
RAG2−/−γc
−/− mouse model (Traggiai et al., 2004) (referred to
hereafter as RAG-hu). In this double mutant immunodeficient
mouse, the RAG2 mutation prevents maturation of lymphocytes
while the absence of functional receptors for IL-2, IL-7 and
other cytokines prevents the expansion of lymphocytes
including NK cells, which can function in graft rejection.Intrahepatic injection of human CD34+ hematopoietic stem cells
leads to de novo multi-lineage human hematopoiesis with the
production of T cells, B cells and dendritic cells (Traggiai et al.,
2004). Structured primary and secondary lymphoid organs
develop in these mice with human cells engrafting in thymus,
bone marrow, spleen, liver and lymph nodes. Of particular sig-
nificance, human immune responses were seen when immu-
nized with tetanus toxoid and infected with Epstein–Barr virus
(Traggiai et al., 2004).
Based on these unique features of multilineage human
hematopoiesis and immune response, here we evaluated this
new humanized RAG-hu mouse model for dengue virus patho-
genesis studies. In vivo DENV challenge resulted in productive
infection associated with viremia, fever and generation of
human anti-dengue antibodies.
Results
Human hematopoiesis and immune cell reconstitution in
RAG2−/−γc
−/− mice
Previous studies have established that RAG2−/−γc
−/− mice
engrafted with cord blood CD34+ cells permit multi-lineage
human hematopoiesis (Baenziger et al., 2006; Berges et al.,
2006; Gimeno et al., 2004; Traggiai et al., 2004). To thoroughly
evaluate their utility for dengue virus infection and immunity
studies, we first constructed RAG-hu mice by intrahepatic
injection of human fetal liver-derived CD34+ cells into con-
ditioned neonatal mice. Our initial experiments evaluated the
transplanted mice to verify the levels of human cell engraftment,
duration of their persistence, tissue distribution and the presence
of different leukocyte subsets including DENV susceptible
monocytes and dendritic cells. Human cell reconstitutions in
blood, bone marrow, thymus, mesenteric lymph nodes, spleen
and liver were evaluated by FACS analysis of cells for the
presence of pan-leukocyte CD45 marker. While engraftment
levels varied between mice, human cells were consistently
detected in all these locations (Fig. 1 and Supplementary Fig. 1).
Additionally, enlargement of lymph nodes, thymus and spleen
was also observed in RAG-hu mice when compared to non-
reconstituted controls (data not shown). Multi-lineage human
hematopoiesis was demonstrated by FACS to detect lineage-
specific markers. CD3+ T cells, CD14+ macrophages, CD19+
CD20+ B cells and both CD11c+CD123− and CD11c−CD123+
dendritic cells were present in reconstituted mice (Fig. 1). Thus
RAG-hu mice harbor the essential cellular components for
dengue virus infection and immune response. Overall, human
immune reconstitution of RAG2−/−γc
−/− mice was similar to that
described previously using similar methods (Gimeno et al.,
2004; Traggiai et al., 2004). We also found that human hema-
topoiesis in these mice persisted for longer than one year (Berges
et al., 2006).
RAG-hu mice support productive dengue virus infection
After constructing RAG-hu mice, and confirming that they
generated a full complement of circulating human hematopoie-
Fig. 2. Dengue plasma viremia in infected RAG-hu mice. Plasma was collected
from infected mice at different times post-infection and viral RNAwas isolated.
Log DENV RNA copies/ml were determined by real-time PCR. Mean viral
loads (±one standard deviation) are shown for mice with constant detectable
viremia (n=9).
Fig. 1. Human cell engraftment in RAG2−/−γc
−/−mice. FACS analysis was performed on cells from either peripheral blood or different lymphoid organs to detect various
leukocyte subsets. CD45+leukocytes (a) and CD3+CD4+T cells (b) in blood were measured using a lymphocyte gate defined by staining normal human CD45+blood
leukocytes. CD14+macrophages (c) were measured using a human monocyte/macrophage gate. CD19+ and/or CD20+B cells in bone marrow (d) and spleen (e) were
gated on CD45+ and CD3− populations. CD11c+ or CD123+dendritic cells (f) were gated on CD45+, HLA-DR+ and Lin1− populations. Dot plots are representative of
at least five blood samples or organs examined from 12 to 20 week old mice. Cells from corresponding tissues of nonhumanized RAG2−/−γc
−/− mice were used as
negative controls for all flow cytometric analyses. Appropriate fluorescently conjugated isotype matched mAbs were also used to control for background staining.
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ceeded to evaluate if these humanized mice were susceptible to
DENV infection. In our initial experiments, we infected mice
which had N20% human leukocytes in blood. Since we were
uncertain about which viral strains, i.e. low passage field strains
versus highly adapted lab strain, would replicate efficiently in
this system a pool of four isolates of DEN-2 serotype (three
primary low-passage Southeast Asian DEN-2 strains, AHF-100,
D9590 and 10649, and a lab DEN-2 strain 16681) was injected
with half of the inoculum delivered by the i/p route and half by
the s/c route to each mouse. Three sets of infections were
performed in which mice received different combination of viral
isolates as described in methods. Nonhumanized control mice
were also infected similarly. Our results showed that RAG-hu
mice supported productive infection leading to sustained
viremia lasting up to 21 days (Fig. 2, Table 1). The viral
loads in plasma reached as high as 106.3 copies/ml. Based on the
quantitative PCR assay we used which has a detection
sensitivity/threshold of 960 copies/ml, two distinct patterns of
infection were evident: (1) mice with high persistent plasma
viremia lasting up to 21 days in which virus was consistently
detectable at every time point tested versus (2) mice with similar
duration of viremia in which viral loads were below the
detection threshold at some time points. Of the eight mice
infected with the 4-strain DEN-2 mixture, five were positive for
plasma viremia on all days whereas three had viremia in whichviral loads fell below the detection levels at some time points
(Table 1). Similarly, of the eight mice challenged with the 3-
strain DEN-2 mixture, four were positive for plasma viremia on
all days tested whereas in the other four, viral detection was
intermittent (Table 1). Both of the two mice challenged with lab
Table 1
Plasma viral load (RNA copies/ml)
Mouse ID Virus challenge Engr a % Day 2 Day 4 Day 6 Day 8 Day 10 Day 12 Day 14 Day 21 Day 42
012 4 DEN-2 b 28 29,676 54,714 24,957 171,435 13,571 410,866 379,665 1,031,811 b960
013 4 DEN-2 21 81,828 263,512 668,036 76,261 185,055 230,994 24,261 41,362 b960
022 4 DEN-2 48 77,893 21,355 6899 7872 96,206 296,825 7659 8800 b960
023 4 DEN-2 28 83,580 46,132 106,709 98,855 32,352 382,032 14,090 186,767 b960
037 4 DEN-2 70 16,203 22,080 177,133 73,926 157,217 101,391 338,376 530,029 b960
011 4 DEN-2 45 106,072 b960 b960 b960 24,694 b960 b960 b960 b960
006 4 DEN-2 37 20,207 b960 b960 b960 b960 b960 305,141 b960 b960
004 4 DEN-2 24 b960 b960 b960 b960 b960 b960 37,068 b960 b960
020 3 DEN-2 c 22 33,667 28,589 61,165 46,989 76,507 43,162 71,995 189,234 b960
027 3 DEN-2 83 100,508 270,023 17,836 23,281 28,392 14,041 48,484 93,605 b960
032 3 DEN-2 28 16,297 60,214 715,155 222,741 248,028 335,043 148,799 40,077 b960
034 3 DEN-2 56 26,903 249,574 1,041,598 513,570 133,444 2,198,366 1,295,985 243,332 b960
042 3 DEN-2 40 b960 9120 b960 b960 201,120 b960 b960 b960 b960
033 3 DEN-2 24 b960 b960 19,200 b960 b960 b960 b960 b960 b960
041 3 DEN-2 20 b960 b960 b960 b960 b960 b960 15,560 b960 b960
026 3 DEN-2 66 b960 b960 b960 b960 b960 b960 10,932 b960 b960
031 1 DEN-2 d 33 16,088 b960 b960 b960 b960 b960 59,156 392,374 b960
048 1 DEN-2 48 b960 b960 b960 10,945 b960 b960 b960 36,341 b960
NH1 e 4 DEN-2 NA b960 b960 b960 27,473 8432 b960 b960 b960 b960
NH2 4 DEN-2 NA b960 b960 b960 b960 b960 b960 b960 b960 b960
NH3 4 DEN-2 NA b960 b960 b960 b960 b960 b960 b960 b960 b960
NH4 4 DEN-2 NA b960 b960 b960 b960 b960 b960 b960 b960 b960
NH5 3 DEN-2 NA 1483 b960 b960 b960 3581 b960 b960 b960 b960
NH6 3 DEN-2 NA b960 b960 3355 b960 b960 b960 b960 b960 b960
NH7 3 DEN-2 NA b960 b960 b960 b960 b960 b960 b960 b960 b960
NH8 3 DEN-2 NA b960 b960 b960 b960 b960 b960 b960 b960 b960
NA=not applicable.
a Percent human engraftment in peripheral blood.
b 4 DEN-2= pool of four DEN-2 strains: 16681, AHF-100, D9590 and 10649.
c 3 DEN-2=pool of three DEN-2 strains: AHF-100, D9590 and 10649.
d 1 DEN-2=DEN-2 16681 lab adapted strain.
e NH1–8=non-humanized mice.
Fig. 3. Fever in dengue virus infected mice. RAG-hu (n=14) and nonhumanized
RAG2−/−γc
−/− (n=8) mice were challenged with DENV and rectal temperature
was measured every 2 days. Nonhumanized mice were also challenged with cell
culture medium containing 10% FBS but lacking DENV (n=5).
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1). The plasma viral load of mice with consistently detectable
viremia remained at approximately 105 copies/ml from day 2
through day 21 (Fig. 2). There was no difference in plasma
viral load between the mice infected with the 4-strain DEN-2
mixture and the 3-strain DEN-2 mixture. Of the eight infected
nonhumanized RAG2−/−γc
−/− mice, five had no detectable
viremia and three had intermittent viral loads below 3×104
copies/ml (Table 1). The latest time point at which a
nonhumanized mouse had detectable viremia was 10 days
post-infection. There was no clear correlation between the levels
of human cell engraftment and the levels of viremia in infected
mice (Table 1). Of the eight mice with N40% human cell
reconstitution in the blood, four had continuous viremia and four
intermittent viremia. Likewise, of the 10 mice with b40%
engraftment, five had continuous viremia and five had
intermittent viremia.
To confirm that viremia detected by PCR was due to a viable
replicating infectious virus, serum of infected animals was
subjected to viral isolation by passage on C6/36 cells. Infectious
virus could be isolated from all three viremic animals tested as
assessed by FACS and PCR (Supplementary Fig. 3). These
results established that RAG-hu mice sustain productive DENV
infection. Since fever is a common feature in acute dengue
infection, we next evaluated whether the infected miceexhibited any increased body temperature. An extended fever
lasting for 14 days and peaking at 35.8 °C on day 8 post-
infection was observed in infected RAG-hu mice. In contrast,
nonhumanized infected and control mice receiving media alone
exhibited a low grade fever lasting only a few days (Fig. 3). The
difference in mean temperature between infected humanized
Table 2
Anti-DENV antibodies detected in RAG-hu mice by ELISA
Mouse 1 week 2 weeks 4 weeks 6 weeks 8 weeks 10 weeks 12 weeks 14 weeks
004 nd nd nd nd IgM IgM IgG IgM IgG IgM IgG
++ + + + ++ + ++
006 nd nd nd nd IgM IgG IgM IgG IgM IgG IgM IgG
+ ++ + ++ + ++ + ++
012 nd nd NEG NEG IgM IgG IgG IgG IgG
+ + + + +
020 NEG NEG NEG NEG IgM IgG IgM IgG IgM IgG IgM IgG
+++ + +++ + +++ + +++ +
027 NEG NEG IgM IgM IgG nd IgM IgG nd nd
+ + + + +
034 nd NEG IgM IgM IgM IgM IgM nd
+++ ++ + + +
042 nd IgM IgM IgM IgM IgM IgM IgM
+ + + + + + +
026 nd NEG NEG NEG IgM IgG IgM IgG IgM IgG nd
+ ++ + +++ + +++
031 NEG NEG NEG NEG nd IgM nd IgM
+ +
048 nd NEG NEG NEG IgG IgG IgG IgG
+ + + +
+=2-fold, ++=4-fold and +++=8-fold greater than background absorbance.
nd=not determined.
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(pb0.001), 10 (pb0.001), 12 (pb0.001) and 14 (p=0.005,
Student's t-test), indicating that the presence of human cells
caused the mouse to develop a greater magnitude fever re-
sponse to infection. We additionally monitored mouse platelet
counts, blood hematocrit, and weight during the 3 weeks of
infection and found no statistically significant change in any
of these parameters (data not shown). Mice also did not
exhibit signs of rash or hemorrhage during infection (data not
shown).
Human immune response and dengue neutralizing antibody
production by RAG-hu mice
Since RAG-hu mice were previously shown to be capable
of human immune responses to antigens such as tetanus toxoid
and EB virus (Traggiai et al., 2004), we wanted to evaluate if
the productive dengue viral infection demonstrated above leads
to a specific antibody response. Antibody responses wereTable 3
Antibody ELISA and neutralization (FNT) titers
Mouse Weeks PI a IgM titer IgG titer FNT50 titer
004 14 1:80 1:2560 1:160
006 14 1:80 1:10,240 b1:40
012 14 b1:10 1:2560 b1:40
020 14 1:1280 1:2560 b1:40
048 12 b1:10 1:160 b1:40
026 10 1:40 1:20,480 b1:40
034 10 1:20 b1:10 1:40
042 10 1:40 b1:10 b1:40
031 14 1:80 b1:10 b1:40
127 12 1:640 b1:10 1:1280
a Post-infection.analyzed using dengue capture ELISAs specific for human
IgM and IgG in order to determine antibody isotype and class
switching.Fig. 4. Immunoprecipitation of DENV polypeptides by infected mouse sera.
DENV infected Vero cells were metabolically labeled with 35S-methionine and
immunoprecipitated with mouse or human sera as described in Materials and
methods. Viral polypeptides were resolved on a 10% SDS-PAGE gel and
visualized by autoradiography. Lanes a and b: uninfected and infected cell
lysates immunoprecipitated with DEN-positive human sera. Lanes c and d:
infected cell lysates immunoprecipitated with infected mouse antiserum and
uninfected control mouse serum, respectively. Immunoprecipitated DENV E
(60 kDa) and capsid (11 kDa) polypeptides are indicated with asterisks.
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DENV-specific human antibody responses to infection. How-
ever, the isotype, magnitude and kinetics of antibody develop-
ment varied between mice (Table 2). DENV-specific IgM was
found in nine mice with its earliest detection at 2 weeks post-
infection while IgG was found in seven mice with its earliest
appearance at six weeks post-infection. In most mice, antibodies
were detected first at eight weeks post-infection. IgG levels
generally stayed constant while IgM levels waned in some
(mouse #s 004, 012 and 034) and remained constant in others
(mouse #s 006, 020, 027, 042, 026 and 031) (Table 2). Serum
IgG titers were generally much higher than that of IgM with a
median positive titer of 1:2560 and a maximum titer of 1:20,480
(Table 3). The median positive titer for IgM was 1:80 and the
maximum titer was 1:1280 (Table 3). Eight DENV-infected
nonhumanized mice and three humanized uninfected mice were
monitored for human DENV-specific IgM and IgG as negative
controls and all were negative through 14 weeks post-infection.
We also evaluated the specificity of the infected mouse antisera
by immunoprecipitation. As seen in Fig. 4, lane C, sera from
mouse #127 which showed neutralization was able to
immunoprecpitate DENV-specific E and capsid polypeptides
in contrast to control uninfected mouse serum.
Neutralizing antibody responses are the most desirable since
they are important in curtailing and controlling viral infections.
Accordingly, we assessed the capacity of RAG-hu mouse
antibodies to neutralize DEN-2 virus using a FACS-based
neutralization assay that has been previously demonstrated to
yield equivalent results to the plaque reduction neutralization
test. Our results showed that sera from three of ten ELISA
antibody-positive mice were able to neutralize dengue virus
infection (Table 3 and Supplementary Fig. 2). In contrast, there
was no evidence of neutralization by sera from all eight
nonhumanized infected mice, three uninfected RAG-hu mice,
and all RAG-hu mice that failed to produce antibodies
(Supplementary Fig. 2 and data not shown).
Discussion
Humanized mice with a full repertoire of circulating human
hematopoietic cells offer novel opportunities to study dengue
viral pathogenesis and immunity. In the present proof-of-
concept experiments, we showed that RAG-hu mice, capable of
de novo multilineage human hematopoiesis, are susceptible to
dengue viral infection and give rise to stable human antibody
responses.
Small animal models such as mice have numerous advan-
tages in general over large animal models such as primates,
including ease of manipulation, lower cost and the larger number
of animals that can be used for experimentation. Previous
standard mouse models using mouse-adapted dengue strains
have been very useful in studying mouse immune responses to
dengue and some basic parameters of in vivo infection (Shresta
et al., 2004, 2006). Similarly, humanized mouse models
transplanted with dengue susceptible cell lines sustained limited
viremia and exhibited some dengue associated pathology (An
et al., 1999; Lin et al., 1998). In a recent advancement, NOD-SCID mice engrafted with cord blood derived human
hematopoietic stem cells also achieved viremia together with
key symptoms of fever and thrombocytopenia (Bente et al.,
2005). However, due to a lack of the necessary combination of
essential human cells, no human immune responses could be
generated in these humanized models thus restricting their
potential. Furthermore, due to high incidence of lymphomas
and consequent early death (Greiner et al., 1998), long-term
pathogenesis studies are not possible in humanized NOD-SCID
mice. In contrast, RAG-hu mice have a normal life span with
the capacity for human hematopoiesis lasting more than a year.
Based on these characteristics, the present RAG-hu system
overcomes most of the previous limitations and thus provides
an improved in vivo animal model for dengue and other
infectious disease research. In fact, recent emerging studies
including our own, showed the utility of this model for
studying long-term HIV infection and virus-induced CD4
helper T cell depletion (Baenziger et al., 2006; Berges et al.,
2006).
Although the presence of functional human T cells, B cells
and dendritic cells has been demonstrated previously in RAG-
hu mice (Traggiai et al., 2004), clear data on circulating human
monocytes were lacking until recently (Baenziger et al., 2006;
Berges et al., 2006). Here we specifically analyzed RAG-hu
mice for their presence and confirmed their existence together
with T, B and dendritic cells. Thus these data establish that
RAG-hu mice harbor both monocytes and dendritic cells
purported to be among the primary dengue viral targets in vivo.
Upon in vivo challenge, all the infected RAG-hu mice showed
persistent dengue viremia with viral levels reaching up to 106.3
viral RNA copies per ml of plasma. Plasma viral loads seen here
are similar to viral loads reported in the humanized NOD-SCID
mouse model (Bente et al., 2005). By successful viral isolation
from viremic animals, we also verified that the circulating virus
as detected by RT-PCR is indeed a viable infectious virus.
Interestingly, viremia persisted for 21 days which is longer than
that seen in humans (2–12 days) (Gubler, 1998). The reason for
this relatively longer viremia is not clear but may reflect
qualitative differences in the innate and adaptive immune
responses of these mice versus the human. We also noted that
while the levels of viremia consistently remained around 105
copies/ml in most mice, viral levels fell below the detection
limit at some time points in some mice. This could be due to
differences in the levels of human cell engraftment and/or levels
of monocytes and dendritic cells in different mice or due to the
physiological status of each animal. Nevertheless, all infected
mice whether infected with either low passage field or highly
adapted lab strains, showed sustainable viremia that lasted up to
21 days. In contrast, there was no detectable viremia in the
majority of nonhumanized control mice although low level
intermittent viremia (b3×104/ml) lasting up to 10 days was
seen in some mice consistent with previous observations that
various nonhumanized mice can develop a low level infection
with dengue virus (Huang et al., 2000a; Paes et al., 2005). Thus,
the higher level of viremia seen in RAG-hu mice is clearly
attributable to more efficient viral replication in engrafted
human cells. The viremic animals also showed lasting fever
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mimicking a key aspect of the natural infection.
A primary distinguishing feature of the current system
compared to all the previous dengue humanized mouse models
is the generation of human-specific antibodies to dengue virus.
Both IgM and IgG antibodies were detected in the majority of
mice that showed viremia (Table 2). Antibodies were detected
first at 8 weeks post-infection in most of the mice. Early IgM
response in some mice followed by the appearance of IgG also
demonstrated antibody class switching in humanized mice.
However, the kinetics of the antibody response were slower
than in humans, and not all mice producing IgM antibodies
progressed to IgG production. In some mice, IgM levels
remained stable for extended periods of time even after IgG
levels increased. IgG titers were generally much higher than
IgM. The level of human cell engraftment in the blood prior to
infection did not correlate with the ability to produce anti-
DENV antibodies. Of the 10 mice which produced anti-DENV
antibodies, five had N40% engraftment whereas the other five
had b40%. It needs to be determined if the overall variation in
antibody responses is related to the levels of individual human
leukocyte subsets.
Since neutralizing antibody is an essential component of
protective immunity, we analyzed the ability of infected mouse
sera to neutralize dengue virus infectivity in vitro. Our results
showed that three of the infected mice produced neutralizing
antibody. Immunoprecipitation data confirmed that mouse
neutralizing antibodies indeed recognize the DENV E protein
which is the neutralization determinant. To our knowledge, this
constitutes the first example of human neutralizing antibody
production in any humanized mouse system in response to
infection with a human virus. Although sera from only 3 of 10
ELISA antibody-positive mice were capable of virus neutraliza-
tion, the present data provides the proof-of-concept that
protective antibodies can be elicited in this system, thus paving
the way for establishing more consistent neutralizing antibody
responses in the future. Differences among the mice in antibody
responses and virus neutralization may be related to variability
in levels of human cell engraftment and/or in the extent of
functional development of specific cell types such as B cells or
CD4+ helper T cells. As mentioned above, dengue viremia seen
in RAG-hu mice is longer than that found in human infections.
This could be due to delayed antibody response in the RAG-hu
mice. Dengue-specific IgM can typically be detected approxi-
mately 5–6 days post onset of symptoms in the human, whereas
in RAG-hu mice detectable dengue-specific antibody appeared
around 8 weeks or later. However, it is interesting to note that all
viremic mice cleared the virus whether or not they produced the
neutralizing antibodies. This could be due to innate immune
mechanisms operating and/or due to exhaustion of virus
susceptible cells that need to be investigated further in future
studies.
Continuous de novo human multilineage hematopoiesis
together with permissiveness for acute dengue viral infection
and specific human response makes this novel RAG-hu mouse
model conducive for testing many important questions on
dengue pathogenesis involving human cells. The role of crossreactive sub-neutralizing levels of antibodies in precipitating
serious and often fatal DHF/DSS via ADE remains to be further
evaluated in a controlled experimental system. With human
antibody immune responses seen in the present model, this
question can now be evaluated systematically. In addition,
differences in virulence and pathogenesis between different
DENV serotypes or strains can be evaluated. In the areas of the
world where different viral strains coexist, simultaneous
infections in the human are possible and their in vivo
interactions are poorly understood. Thus the interplay among
multiple strains infecting simultaneously can now be dissected.
Since dengue is a mosquito-borne virus, the ability of infected
mosquitoes to infect RAG-hu mice can now be examined with
novel future experiments focusing on transgenic mosquitoes
which are dengue-resistant (Franz et al., 2006). The involve-
ment of different human cell types involved in disease
pathogenesis and the specific cytokines they secrete in response
to viral infection in vivo can also now be evaluated.
The present literature is conflicting regarding the primary
cellular receptors in different cell types susceptible to dengue
viral infection. The current model that uses hematopoietic
stem cells to generate RAG-hu mice is particularly suitable to
determine the roles played by putative cellular receptors. For
example, gene knock-down strategies such as use of siRNAs
or ribozymes can be put to work in this model similar to that
we demonstrated previously with HIV and SCID-hu model
systems in which viral molecules and cellular receptors were
down-regulated (Anderson and Akkina, 2005; Bai et al.,
2000; Banerjea et al., 2003). In one such experiment, CD34+
cells can be transduced with siRNA containing viral vectors
for specific receptor silencing. RAG-hu mice can be produced
by using these cells lacking these receptors and subsequently
challenged with dengue virus to determine their susceptibility
to infection.
In summary, the RAG2−/−γc
−/− mouse model for dengue
virus described in this study provides a unique research tool for
addressing many important and timely questions about dengue
virus infection and immunity.
Materials and methods
Generation of humanized RAG2−/−γc
−/− mice (RAG-hu mice)
and tissue collection
Humanized RAG-hu mice were constructed essentially as
described by Traggiai et al. (2004) and Berges et al. (2006).
Briefly, newborn RAG2−/−γc
−/− mice were irradiated with a
single dose of 3.5 Gy generated from a Cs-137 source. At 1–
24 h post irradiation, mice were injected intra-hepatically with
4×105–1×106 human CD34+hematopoietic progenitor cells.
Transplanted mice were screened for human cell engraftment at
12+ weeks post-reconstitution. Peripheral blood was collected
by tail bleed, and red blood cells were lysed using the Whole
Blood Erythrocyte Lysing Kit (R&D Systems) according to the
manufacturer's protocol. The white cell fraction was stained
with antibodies against the human pan-leukocyte marker CD45
and analyzed by FACS to verify engraftment.
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Human fetal liver-derived CD34+ cells were isolated and
cultured in cytokine media containing IL-3, IL-6 and SCF as
described previously (Akkina et al., 1994; Bai et al., 2000).
CD34+ cells were maintained in cytokine media for 24 h, at
which time they were injected into newborn irradiated RAG2−/−
γc
−/− mice. C6/36 and Vero cell lines were cultured in
Dulbecco's modified Eagle's medium (DMEM) containing
10% heat inactivated fetal bovine serum (FBS). The viruses
used in this study included the DEN-2 high-passage laboratory
strain 16681 as well as primary low-passage clinical DEN-2
isolates: D9590 from Sri Lanka, 10649 from the Philippines and
AHF-100 from Thailand. DEN-2 viral stocks were generated by
amplification in C6/36 cells and titrated on Vero cells by flow
cytometry FACS-based assay with the 4G2 antibody as
previously described (Lambeth et al., 2005).
Flow cytometry
To identify multi-lineage hematopoetic development, fluor-
escently labeled mAbs to the following cellular markers were
obtained from Caltag Laboratories (Invitrogen) and used
according to the manufacturer's instructions: CD45, CD3,
CD4, CD19, CD20, CD14, CD123, CD11c, Lin1 and HLA-DR.
Antibodies were conjugated to FITC, PE, APC, PE-Cy5 or
APC-Cy7. The leukocyte gate was defined by CD45 staining of
normal human blood. In all analyses of human cell engraftment,
cells from nonhumanized RAG2−/−γc
−/− mice were used to
control for nonspecific staining of mouse cells. Dengue virus
infection of Vero cells was assayed by flow cytometry
according to a published method (Lambeth et al., 2005) using
the 4G2 antibody conjugated to Alexa-488. Isotype antibodies
were used to control for background staining. Cells were
analyzed using an EPICS XL-MCL flow cytometer (Coulter).
Multicolor flow cytometry was conducted using a Becton
Dickinson FACSAria.
Dengue viral infection of RAG-hu mice and clinical monitoring
RAG-hu mice with human lymphoid cell reconstitution
levels in the blood ranging from 20 to 80% were challenged
with DEN-2 serotype viruses. Initial infections used a pool of
four DEN-2 viral strains consisting of low passage field as well
as lab adapted viruses. Later experiments used either pooled low
passage viral isolates or the lab adapted virus alone. Mice were
challenged with 1×106 IU of individual virus isolates or pooled
virus via intraperitoneal (100 μl) and subcutaneous (100 μl)
routes. Mouse body temperature was monitored every 2 days
using a RET-3 rectal thermo-probe coupled to a Digi-Sense
digital thermometer (Eutech Instruments). Mouse weight was
monitored using an EK-1200i balance (AND) every 2 days for a
period of 21 days post-injection. Mouse platelet count and
hematocrit were determined at pre-infection, 1 week, 2 weeks
and 3 weeks post-infection using an Advia 120 hematology
flow cytometer (Bayer) and validated by manually counting
blood smears.Real-time qPCR for plasma viral load determination
Total RNA isolated from mouse plasma using the QIAamp
Viral RNA kit (Qiagen) was reverse transcribed into cDNAwith
the SuperScript III System for First Strand Synthesis for RT-
PCR (Invitrogen) using DENVantisense primer NS5R (Kong et
al., 2006). Real-time qPCR was carried out using the Platinum
SYBR green PCR kit (Invitrogen) in a Biorad iCycler iQ
thermocycler. DENV primers NS5F and NS5R (Kong et al.,
2006) were used to initiate PCR with 5 μl cDNA as a template.
Reaction conditions were as follows: 50 °C for 2 min; 95 °C for
2 min; 45 cycles of 95 °C for 15 s, 58 °C for 30 s and 72 °C for
30 s; 72 °C for 5 min. Levels of DENV RNA amplified by this
two-step qRT-PCR method were determined by comparison to a
standard curve generated against known quantities of DEN-2
16681 NS5 RNA, which were produced by transcription and
quantified as previously described (Kong et al., 2006).
Dengue viral isolation from infected RAG-hu mice
Viral isolation from the sera of DENV-infected mice was
done in C6/36 cells. The supernatants from the second passage
were used to infect Vero cells which were subjected to FACS
analysis 24 h later as described above (36). Additionally virus
from the culture supernatants was also detected by PCR. Briefly,
RNA was extracted from 140 μl of 2nd passage supernatant
using the QIAamp Viral RNA kit (Qiagen). RT-PCR was
conducted with sense primer NS5-5 (AATCTCCATCTT-
GAAGGAAAGTGTG) and antisense primer NS5-6 (GCCTCT-
TGGTGTTGGTCTTTGC) using the SuperScriptIII One-Step
RT-PCR with Platinum Taq kit (Invitrogen) according to the
manufacturer's instructions and recommended thermocycling
conditions.
Detection of human anti-dengue antibodies by ELISA and
immunoprecipitation
Levels of human anti-dengue antibodies present in mouse
serum were determined using commercial human IgM and IgG
dengue capture ELISAs (Panbio). Sera from DENV-infected
nonhumanized RAG2−/−γc
−/− mice as well as humanized
uninfected RAG2−/−γc
−/− mice were used as negative controls.
Positive controls included a known anti-DENV antibody-
positive human serum as well as samples provided with the
ELISA kits. Samples were considered positive if the OD450 was
greater than two times the background absorbance level. Serum
samples which produced a positive IgM or IgG ELISA reading at
a 1:10 dilution were then serially diluted two-fold up to 1:81,920
and assayed by ELISA. To evaluate the specificity of infected
mouse sera to individual viral polypeptides, radioimmunopre-
cipitation was carried out as previously described (Akkina et al.,
1987). Briefly, DEN-2 16681 viral infected Vero cells 24 h post-
infection were pulse labeled with 35S-methionine (100 μCi/ml)
for 4 h. Cell lysates were made and clarified by centrifugation
and subjected to immunoprecipitation with either infected
mouse sera or polyclonal human sera. To immunoprecipitate
both IgG and IgM antibodies, a mix of Protein G, Protein A and
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cleared using 10 μl of bead slurry per milliliter of lysate. Viral
polypeptides were immunoprecipitated with 10 μl of either
human or mouse sera. Lysates from control uninfected cells were
treated similarly. The immunoprecipitates were resolved on a
10% SDS-PAGE gel and subjected to autoradiography.
FACS-based dengue virus neutralization assay
The ability of humanized RAG2−/−γc
−/− mouse generated
antibodies to neutralize DEN-2 virus was determined using a
FACS neutralization test (FNT) modified from a previously
described method (Lambeth et al., 2005). Mouse serum was
mixed with 0.2 MOI DEN-2 16681 virus (determined relative
to 4×105 cells) in a total volume of 200 μl. The 200 μl
serum-virus mixture was placed on ice for 30 min followed
by room temperature for 15 min. This mixture was used to
inoculate 4×105 Vero cells in a single well of a 12-well plate.
At 24 h post-infection, single-cell suspensions were made and
subjected to FACS analysis after staining with 4G2 antibody
as described (Lambeth et al., 2005). Sera from DENV-infected
nonhumanized RAG2−/−γc
−/− mice as well as uninfected
humanized RAG2−/−γc
−/− mice were used as negative controls
for neutralization. The FNT50 was defined as the highest two-
fold dilution of serum which produced N50% reduction in
DENV infection of Vero cells.
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